Obesity is a heterogeneous disease and is associated with comorbidities such as @entity6 , @entity65 and @entity5 . Several studies have examined the role of dysfunctional adipose tissue in the pathogenesis of @entity28 , highlighting the contrasting properties and impact of distinct fat compartments, sometimes with contradictory results. Dysfunctional adipose tissue involves enlargement, or @entity1184 , of pre-existing fat cells, which is thought to confer increases in cardiometabolic risk, independent of the level of @entity28 per se. In this article, we critically analyze available literature that examined the ability of adipocyte cell size to predict @entity209 in @entity1 . Many studies demonstrate that increased fat cell size is a significant predictor of altered blood lipid profiles and @entity413 -insulin homeostasis independent of @entity1386 indices. The contribution of visceral @entity1386 to these associations appears to be of particular importance. However, available studies are not unanimous and many fat depot-specific aspects of the relationship between increased fat cell size and cardiometabolic risk or parameters of adipose tissue dysfunction are still unresolved. Methodological factors such as the approach used to express the data may represent significant confounders in these studies. Additional studies should consider the fact that the relationship between fat cell size and common @entity1386 indices is non-linear, particularly when reaching the obese range. In conclusion, our analysis demonstrates that fat cell size is a significant predictor of the cardiometabolic alterations related to @entity28 . We propose that adipocyte @entity1184 , especially in the visceral fat compartment, may represent a strong marker of limited hyperplasic capacity in subcutaneous adipose tissues, which in turn is associated with the presence of numerous cardiometabolic alterations.

Adipocyte size as a determinant of XXXX .

@entity1 :: ('9606', 'Species') :: ['humans'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity6 :: ('MESH:D003920', 'Disease') :: ['type 2 diabetes mellitus'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy'] @entity1386 :: ('MESH:D018205', 'Disease') :: ['adiposity'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic disease and adipose tissue dysfunction'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']
@entity209 :: (MESH:D008659,Disease) :: ['metabolic disease and adipose tissue dysfunction']
